Yes, Botox is FDA approved. It was first approved for medical use in 1989 and received its cosmetic approval on April 12, 2002. Today it holds FDA approval for a surprisingly wide range of conditions, from forehead wrinkles to chronic migraines to overactive bladder. Both the cosmetic and therapeutic versions contain the same active ingredient, onabotulinumtoxinA, but they’re marketed under separate labels: Botox Cosmetic for aesthetic uses and Botox for medical conditions.
FDA-Approved Cosmetic Uses
Botox Cosmetic is approved for adults who want to temporarily reduce the appearance of moderate to severe facial lines. The specific approved areas are:
- Glabellar lines: the vertical “11” lines between your eyebrows
- Lateral canthal lines: crow’s feet at the outer corners of your eyes
- Forehead lines: horizontal creases across the forehead
- Platysma bands: vertical bands that become visible on the neck
These are the only cosmetic applications that carry full FDA approval. Many other popular aesthetic uses, like slimming the jawline through masseter injections or smoothing the chin, are performed off-label. Off-label doesn’t mean unsafe or ineffective, but it does mean the FDA hasn’t formally reviewed evidence for that specific use.
FDA-Approved Medical Conditions
The medical side of Botox’s approval list is extensive and continues to grow. The FDA has cleared it to treat the following conditions in adults:
- Chronic migraine: defined as 15 or more headache days per month, with headaches lasting four hours or longer. Botox is approved specifically for prevention, not for treating individual migraine attacks.
- Cervical dystonia: a painful condition where neck muscles contract involuntarily, pulling the head into abnormal positions.
- Upper limb spasticity: tightness and stiffness in the muscles of the arm, wrist, or hand, often following a stroke or brain injury.
- Severe underarm sweating: formally called primary axillary hyperhidrosis. The FDA approval applies only to underarm sweating that hasn’t responded to prescription antiperspirants. Botox is not approved for excessive sweating on the palms, feet, or other body areas.
- Overactive bladder: for adults experiencing urge incontinence, urgency, and frequency who haven’t gotten adequate relief from standard bladder medications.
- Neurogenic bladder dysfunction: urinary incontinence caused by neurological conditions like spinal cord injury or multiple sclerosis, again only after other medications have failed.
- Blepharospasm: involuntary, forceful closing of the eyelids, approved for patients 12 and older.
- Strabismus: misalignment of the eyes (crossed eyes), also approved for patients 12 and older.
Blepharospasm and strabismus were actually among the earliest approved uses, predating the cosmetic approval by over a decade.
Pediatric Approvals
Botox has limited FDA approval for children. It is licensed for treating spasticity in children two years of age or older who have foot deformities caused by persistent muscle tightness, most commonly associated with cerebral palsy. Blepharospasm and strabismus are approved starting at age 12. All cosmetic uses are approved only for adults.
Off-Label Uses Are Common
A significant portion of Botox use in clinical practice falls outside its official FDA-approved indications. Dermatologists and other specialists use it off-label for conditions including keloids and hypertrophic scars, rosacea-related facial flushing, oily skin and enlarged pores, Raynaud’s phenomenon (poor circulation in the fingers), and certain rare skin diseases like Hailey-Hailey disease and hidradenitis suppurativa. Hair loss, psoriasis in skin folds, and postherpetic neuralgia (lingering pain after shingles) have also been treated with off-label Botox injections.
In the aesthetic world, masseter reduction for jawline slimming, trapezius injections for a slimmer neck and shoulder profile, and “micro-Botox” for skin texture are all off-label. These uses are widespread in cosmetic practices but haven’t gone through the formal FDA review process for those specific indications.
The FDA’s Safety Warning
Botox carries the FDA’s most serious safety label, a boxed warning, about the potential for the toxin to spread beyond the injection site. When this happens, it can cause symptoms like generalized muscle weakness, difficulty swallowing, vision changes, and breathing problems. These effects have been reported anywhere from hours to weeks after injection.
The risk is highest in children being treated for spasticity, but it can occur in adults as well, particularly those who already have an underlying condition affecting their muscles or nerves. Swallowing and breathing difficulties from toxin spread can be life-threatening, and deaths have been reported. This warning applies to all botulinum toxin products, not just Botox specifically.
For most people receiving standard cosmetic doses in a clinical setting, serious complications are rare. The boxed warning reflects the full range of medical uses, including higher-dose therapeutic applications, where the risk profile is different from a typical cosmetic treatment.